Florian Scherer MD

Abstract submissions are open for the AACR/ICML Advances in Malignant Lymphoma meeting!! June 24-27 in Philadelphia. Please retweet. aacr.org/meeting/advanc…

🚨We are seeking a candidate for the PhD fellowship supported by ISCIII-PFIS at @VHIO 🧠Project: Overcoming immune scape by boosting antitumoral potential of macrophages in patients with CNS lymphoma 📩macrespo@vhio.net @Hemato_Vhebron linkedin.com/jobs/view/4356… #lymphoma #Phd

🚨Just out @CCR_AACR 🚨 V proud of our manuscript on polatuzumab efficacy by cell of origin in DLBCL We show COO by Hans predicts pola sensitivity in 740 pts Pts w R/R non-GCB DLBCL have higher ORR, CRR & PFS Massive thanks @dgermain21 & collabs! aacrjournals.org/clincancerres/…

📣#ESHCLL2026: PRELIMINARY SCIENTIFIC PROGRAMME NOW LIVE! ➡️bit.ly/4cfagyf 4th Translational Research Conference on Chronic Lymphocytic Leukaemia March 5–7, 2026 / Stockholm, Sweden Chairs : Jennifer Brown Paolo Ghia, @HallekMichael #ESHCONFERENCES #CLLsm #Lmsm

Grateful to be here in lovely Freiburg, Germany for the 5th International Liquid Biopsy Symposium, organized by my good friend @FSchererMD at the University of Freiberg! @max_diehn will be giving the Keynote. I’ll be presenting our work on urine cell-free nucleic acids tmrw.

Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

🎯 Time to register for the 5th International Liquid Biopsy Symposium in Freiburg, Germany — Sept 19–20, 2025! 🌍 Join us on-site or virtually 🧬 Amazing lineup of speakers 📢 Abstract submission now open! 🔗 Register: uniklinik-freiburg.de/liquid-biopsy-…

Our very own CMO and co-founder, David Kurtz, was featured on the #ASCODailyNews discussing the incorporation of #ctDNA-MRD in NCCN Guidelines for B-cell Lymphoma. Read the article here: bit.ly/4jCKiHm #PrecisionMedicine #ctDNA #Diagnostics #MRD @ASCO

Excited to share our study describing a new liquid biopsy method called RARE-Seq for analyzing cell-free RNA (#cfRNA) that is out today in @Nature. 1/15 rdcu.be/eh1Nt

We are very thankful for the great collaborations and support of all co-authors including @JurikMutter @StefanAlig @max_diehn @AshAlizadeh @LizSchorb and the support by @EKFStiftung @dfg_public @CRIIONorg @dgimev @DKTK_ @JCLStiftung

rdcu.be/eg3cT.

Super happy to share our paper just published in @LeukemiaJnl, in which we demonstrate that minimal-invasive CNS lymphoma identification by ctDNA profiling in CSF can guide treatment and surgical management in daily clinical practice and large patient cohorts.

@EKFStiftung @L_Bunse @r_sankowski Many thanks @EKFStiftung for this awesome prize and the invaluable support of our lab! Congrats to the other awardees, very well deserved!

Die #EKFS Publikationspreise 2024 gehen an: 🔹Prof. Dr. Frederik Damm 🔹PD Dr. Florian Scherer (@FSchererMD) 🔹Dr. Ria Schönauer 🔹Dr. Dr. Lukas Bunse (@L_Bunse) 🔹PD Dr. Roman Sankowski (@r_sankowski) ekfs.de/aktuelles/pres…

Please RT and register: West German Lymphoma Symposium ⁦@HamatologieUk⁩ ⁦⁦@UniklinikEssen ⁦@MedEssen ⁦@unidue⁩ @dgho_eV⁩ #sfb1530 lymphoma-symposium.de

Parallel to a great poster presentation by Dr. Miriam Mozaffari at #ASH2023, our new study was published in @BloodCancerJnl: Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure

@ekocakavuk @Brainlab @NeuroOnc Yes, we showed recently in our JCO paper that ctDNA levels in plasma correlate with tumor volume (see below). Yet, ctDNA remained prognostic in multivariate analyses, suggesting an independent role for risk stratification.

@FSchererMD @Brainlab @NeuroOnc Congratulations! Have you correlated tumor volume with ctDNA presence/levels? - I wonder if both metrics basically show that more tumor is bad for survival.

Excited to share our latest study on improved early outcome prediction in CNS lymphoma by semi-automated 3D MRI tumor volumetry (@Brainlab and itk-SNAP) and ctDNA profiling, published in Neuro-Oncology @NeuroOnc academic.oup.com/neuro-oncology…